Ожирение и онкологические заболевания: старая проблема в новом свете

1. Berstein L.M. Macrosomy, obesity and cancer. New York: Nova Sci. Publ., 1997. 195 p.

2. Берштейн Л.М. Внегонадная продукция эстрогенов (роль в физиологии и патологии). СПб.: Наука, 1998. 172 с.

3. Берштейн Л.М. Онкоэндокринология:традиции, современность и перспективы. СПб.: Наука, 2004. 343 с.

4. Berstein L.M. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett. 2005;224:203-212.

5. Берштейн Л.М. Гормоны жировой ткани (адипоцитокины): онтогенетический и онкологический аспект проблемы. // Усп. геронтол. 2005. Вып. 16. С. 51-64.

6. Дедов И.И., Мельниченко Г.А. (ред.). Ожирение. М.: МИА, 2004.

7. Дедов И.И., Мельниченко Г.А., Фадеев В.В. Эндокринология. М.: Медицина, 2000. 631 с.

8. Дильман В.М. Четыре модели медицины. Л.: Медицина, 1987. 287 с.

9. Семиглазов В.Ф., Нургазиев К.Ш., Арзуманов А.С. Опухоли молочной железы (лечение и профилактика). Алмааты, 2001. 344 с.

10. Adami H.-O., Signorello L.B., Trichopoulos D. Towards an understanding of breast cancer etiology.Semin. Cancer Biol. 1998;8:255-262.

11. Ballard-Barbash R., Swanson C.A. Body weight: estimation of risk for breast and endometrial cancers. Am. J. Clin. Nutr.1996;63 (Suppl. 3):437-441.

12. Boyd N.F., Cousins M., Lockwood C, Trichler D. Dietary fat and breast cancer risk. The feasibility of a clinical trial of breast cancer prevention. Lipids. 1992;27:821-827.

13. Brakenhielm E., Veitonmaki N., Cao R. et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl. Acad. Sci. (USA). 2004;101:2476-2481.

14. Calle E.E., Rodriguez C, Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New Engl. J. Med. 2003;348:1625-1638.

15. Catalano S., Mauro L, Marsico S. et al. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J. Biol. Chem. 2004;279:19908-19915.

16. Chlebowski R.T., Stefanick M.l., McTiernan A. et al. Dietary Fat Reduction in Postmenopausal Women with Primary Breast Cancer: Phase III Women's Intervention Nutrition Study (WINS). ASCO Proceed. 2005.

17. Facchini F.S., Hua N., Abbasi F., Reaven G.M. Insulin resistance as a predictor of age-related diseases. J. Clin. Endocrinol. Metab. 2001;86:3574-3578.

18. Fain J.N., Madan A.K., Hiler M.l. et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273-2282.

19. Fernandez-Real J.M., Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Rev. 2003;24:278-301.

20. Forbes G.B. Human body composition. Growth, aging, nutrition and activity. NY-Berlin-Heidelberg: Springer-Verlag, 1987. 350 p.

21. Fruehwald-Schultes В., Oltmanns K.M., Toschek B. et al. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism. 2002;51:531-536.

22. Fukuhara A., Matsuda M., Nishizawa M. et al. Visfatin:a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426-430.

23. Furukawa S., Fujita Т., Shimabukuro M. et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004;114:1752-1761.

24. Henderson B.E., Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis. 2000;21:427-433.

25. Hovey R.C., McFadden T.B., Akers R.M. Regulation of mammary gland growth and morphogenesis by the mammary fat pad: a species comparison. J. Mammary Gland Biol. Neoplasia. 1999;4:53-68.

26. Iyengar P., Combs T:, Shah S.J. et al. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene. 2003;22:6408-6423.

27. Kaaks R, Berrino F, Key T. et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 2005;97:755-765.

28. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metabol. 2004;89:2548-2556.

29. Kroenke C.H., Chen W.Y., Rosner В., Holmes M.D. Weight, weight gain, and survival after breast cancer diagnosis. J. Clin. Oncol. 2005;23:1370-1378.

30. Lawlor DA, Smith GD, Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer:findings from the British Women's Heart and Health Study. Cancer Causes Control. 2004;15:267-275.

31. Levine J.A., Lanningham-Foster L.M., McCrady S.K. et al. Interindividual variation in human posture allocation: possible role in human obesity. Science. 2005;307:584-586.

32. Lew E.A., Garfinkel L. Variations in mortality by weight among 750 000 men and women. J. Chron. Dis.1979;32:563-576.

33. Mantzoros C, Petridou E., Dessypris N. et al. Adiponectin and breast cancer risk. J. Clin. Endocrinol. Metabol. 2004;89:1102-1107.

34. Matsuzawa Y., Shimomura I., Kihara S., Funahashi T. Importance of adipocytokines in insulin resistance and obesity-related diseases. Horm. Res. 2003;60(Suppl. 3):56-59.

35. Matsuzawa Y., Funahashi Т., Kihara S., Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vase. Biol. Med. 2004;24:29-34.

36. Miyoshi Y., Funahashi Т., Kihara S. et al. Association of serum adiponectin levels with breast cancer risk. Clin. Cancer Res. 2003;9:5699-5704.

37. Moreland L.W. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics. 2004;22(Suppl. 2):39-53.

38. Nilsson M., Johnsen R., Ye W. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms: risk of esophageal adenocarcinoma. JAMA. 2003;290:66-72.

39. Paltoo D., Woodson K., Taylor P. et al. Pro 12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer in a large cancer prevention study. Cancer Lett. 2003;191:67-74.

40. Petridou E., Belechri M., Dessypris N. et al. Leptin and body mass index in relation to endometrial cancer risk. Ann. Nutr. Metab.2002;46:147-151.

41. Phillips S.A., Ciaraldi T., Kong A. et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003;52:667-674.

42. Reaven G. Pathophysiology of insulin resistance in human disease. Physiol. Rev. 1995;75:473-486.

43. Rose D., Komninou D., Stephenson G.D. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes. Rev. 2004;5:153-165.

44. Seckl J.R., Morton N.M., Chapman K.E., Walker B.R. Glucocorticoids and 11 beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Progr. Horm. Res. 2004;59:359-393.

45. Sesti G., Perego L., Cardellini M. et al. Impact of Common Polymorphisms in Candidate Genes for Insulin Resistance and Obesity. J. Clin. Endocrinol. Metabol. 2005;90:5064-5069.

46. Severson R.K., Grove J.S., Nomura A.M.Y., Stemmermann G.N. Body mass and prostatic cancer: a prospective study. Brit. Med. J. 1988;297:713-715.

47. Tannenbaum A., Silverstone H. Nutrition in relation to cancer. Adv. Cancer Res. 1953;1:451-501.

48. Tessitore L., Vizio В., Pesola D. et al. Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. Int. J. Oncol. 2004;24:1529-1535.

49. Tomlinson J.W., Stewart P.M. The functional consequences of 11 beta-hydroxysteroid dehydrogenase expression in adipose tissue. Horm. Metab. Res. 2002;34:746-751.

50. Ursin G., Longnecker M:, Haile R.W., Greenland S. A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology. 1995;6:137-141.

51. Weinberg R.A. How cancer arises. Sci. Amer. 1996;275:32-41.

52. Yazdani-Biuki В., Stelzl H., Brezinschek H. et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur. J. Clin. Invest. 2004;34:641-642.

53. Zhu Z., Jiang W., McGinley J.N..Thompson H.J. 2-deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res. 2005;65:7023-7030.

54. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J. Intern. Med. 2000;247:301-310.